-+ 0.00%
-+ 0.00%
-+ 0.00%

Stephens & Co. Maintains Overweight on Cytek Biosciences, Lowers Price Target to $4.75

Benzinga·05/13/2026 15:25:02
Listen to the news
Stephens & Co. analyst Mason Carrico maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and lowers the price target from $5.5 to $4.75.